All sponsors

Beijing InnoCare Pharma Tech Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS23
PHASE 3 / 2-310
RECRUITING16
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO50%

Delay Index: of 10 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.2 months). See all sponsors →

Open Beijing InnoCare Pharma Tech Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Tafasitamab and Lenalidomide
NCT05552937
P2RecruitingDLBCL502025-04
ICP-192
NCT05678270
P2RecruitingIntrahepatic Cholangiocarcinoma (ICC)702026-05
ICP-488 Tablets
NCT06842199
P3RecruitingPlaque Psoriasis Patients3832026-05
Orelabrutinib (ICP-022)
NCT04014205
P1/2Active, not recruitingPart 1:r/r B-cell Malignancies; Part 2:B-cell Malignancies812026-06-30 (+70 mo)
ICP-332 Tablets
NCT06775860
P3RecruitingAtopic Dermatitis5522026-11-25
CM355
NCT05210868
P1/2Active, not recruitingHematoma1842026-12-28
ICP-322
NCT07236099
P2RecruitingPrurigo Nodularis (PN)1352027-03
ICP-488 Tablets
NCT07440537
P2RecruitingCutaneous Lupus Erythematosus (CLE)1052027-03
ICP-B381
NCT07901413
P1/2Not yet recruitingAdvanced Solid Tumor3482027-09
ICP-248
NCT07082686
P2RecruitingRelapsed or Refractory Mantle Cell Lymphoma (MCL)752027-12 (+24 mo)
ICP-723
NCT05745623
P1/2RecruitingAdvanced Solid Tumors Harboring NTRK Fusion; Primary Central Nervous System Tumors Harboring NTRK Fusion702027-12-25 (+43 mo)
ICP-723
NCT04685226
P1/2RecruitingSolid Tumors3102028-01-25 (+61 mo)
ICP-490
NCT06845241
P1/2Not yet recruitingRelapsed or Refractory Non-Hodgkin Lymphoma682028-07
Orelabrutinib
NCT06082102
P3RecruitingRelapsed/Refractory Marginal Zone Lymphoma3242028-08-31 (+12 mo)
Tafasitamab
NCT06521255
P3RecruitingDLBCL2442028-09
ICP-332 Tablets
NCT07378527
P2/3RecruitingChronic Spontaneous Urticaria (CSU)3442028-09
Orelabrutinib
NCT07896590
P3Not yet recruitingRelapsed/Refractory Marginal Zone Lymphoma (MZL)2922028-10
ICP-488 Tablets
NCT07727486
P2Not yet recruitingPrimary Sjögren's Syndrome2402028-12
ICP-332 Tablets
NCT07047612
P2/3RecruitingNon Segmental Vitiligo6032029-04
Mesutoclax (ICP-248)
NCT07925190
P3RecruitingAcute Myeloblastic Leukemia3182029-12
ICP-248
NCT06378138
P2/3RecruitingHematologic Malignancies2262030-11-25
ICP-B208
NCT07617493
P1/2RecruitingAdvanced Solid Tumor5512030-12
ICP-248
NCT07784101
P3Not yet recruitingRelapsed or Refractory Mantle Cell Lymphoma (MCL)2802032-10